A study for the effects of ingestion of collagen octapeptide (Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro) on endothelial function in healthy adult with lower endothelial function.

A study for the effects of ingestion of collagen octapeptide (Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro) on endothelial function in healthy adult with lower endothelial function. - A study for the effects of ingestion of collagen octapeptide on endothelial function in healthy adult.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031071

Enrollment

Registered

2018-02-02

Start date

2018-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Ingestion of collagen octapeptide (Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro) for 8 weeks. Ingestion of placebo for 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Healthy adult who aged 20-64 years old. (2) FMD value 4.0-7.0% (3) BMI less than 25.0 kg/m 2

Exclusion criteria

Exclusion criteria: (1) Subjects who take pharmaceutical agent, functional food, or supplement that may affect the study. (2) Subjects who routinely use food rich in collagen. (3) Ineligible subjects with abnormal laboratory value or cardiopulmonary function. (4) Subjects having possibilities for emerging allergy related to the study. (5) Subjects who are under medication. (6) Subjects who are under treatment or have a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease). (7) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination. (8) Subjects who have habits affecting research results, such as doing shift work day and night, or Subjects who have a plan that affect research results such as day and night shift work and overseas. (9) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study. (10) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating. (11) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire. (12) Subjects who cannot obey the restriction item (prohibited matter) during the study. (13) Subjects who are hypertension stage I (SBP>=140 mmHg and/or DBP>=90 mmHg). (14) Subjects who have baPWV value 1400 cm/s or more. (15) Subjects judged as unsuitable for the study by the investigator for other reasons.

Design outcomes

Primary

Measure	Time frame
Flow Mediated Dilation (FMD)	—

Secondary

Measure	Time frame
Fatigue sensation (VAS) Athens Insomnia Scale Pittsburgh Sleep Quality Index	—

Countries

Japan

Contacts

Public ContactShingo Yamamichi

TTC Co.,Ltd Clinical Research Planning Department

s.yamamichi@ttc-tokyo.co.jp03-5459-5329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026